Drug Type ASO |
Synonyms MyMir, HC2101, WGI-2101 |
Target |
Action inhibitors |
Mechanism miR-21 inhibitors(microRNA 21 inhibitors), Epigenetic drug, RNA interference |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | United States | 28 Apr 2024 | |
Non-Small Cell Lung Cancer | Preclinical | China | 28 Apr 2024 |